Ubiquitome specializes in portable, cloud-connected qPCR devices designed to provide rapid and accurate genetic testing in various settings, including field environments, clinics, and agricultural sites. Their flagship product, the Liberty16, is a compact, battery-operated real-time PCR machine that enables users to conduct molecular testing with results available in as little as 20 minutes. This device is particularly significant for its FDA-EUA approval for the SalivaDirect protocol, which facilitates the detection of SARS-CoV-2 RNA, making it a vital tool in the ongoing response to the COVID-19 pandemic. The Liberty16 is designed for ease of use, featuring Bluetooth connectivity to an iPhone app for seamless data sharing and monitoring.

Ubiquitome's technology emphasizes accessibility and affordability, aiming to overcome the limitations of traditional lab-bound testing methods that often delay diagnosis and treatment. The Liberty16's portability allows for on-site testing, which is crucial in resource-limited settings where timely disease detection can significantly impact health outcomes. The device is built to withstand field conditions and supports a wide range of applications, from human health diagnostics to environmental monitoring and agricultural assessments. Ubiquitome's commitment to continuous improvement and custom assay development further enhances its potential to revolutionize molecular testing across various sectors.

New Zealand

Ubiquitome's mission is to enable universal access to genomic information through ubiquitous cloud connected, genetic analysis devices.

Ubiquitome

Company Details